Kolon Life Science

Kolon Life Science Current Liabilities

The Current Liabilities of Kolon Life Science (102940.KQ) as of Nov 3, 2026 is 12.93 B KRW. In the previous year, Current Liabilities was 133.43 B KRW — a change of -90.31% (lower).

Current Liabilities

12.93 BKRW

YoY

-90.31%

Last updated:

Current Liabilities of Kolon Life Science is 2025 12.93 B KRW. Current Liabilities of Kolon Life Science was 2024 133.43 B KRW. It decreases by -90.31% lower compared to the previous year.

The Kolon Life Science Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
77.01 B KRW
Jan 1, 2019
126.17 B KRW
Jan 1, 2020
145.15 B KRW
Jan 1, 2021
95.47 B KRW
Jan 1, 2022
94.39 B KRW
Jan 1, 2023
113.59 B KRW
Jan 1, 2024
133.43 B KRW
Jan 1, 2025
12.93 B KRW
The Kolon Life Science Current Liabilities history
YEARCurrent LiabilitiesYoY
12.93 BKRW-90.31%
133.43 BKRW+17.47%
113.59 BKRW+20.34%
94.39 BKRW-1.13%
95.47 BKRW-34.23%
145.15 BKRW+15.04%
126.17 BKRW+63.84%
77.01 BKRW+22.13%
63.06 BKRW-10.19%
70.21 BKRW+82.65%
38.44 BKRW-2.20%
39.31 BKRW-15.10%
46.30 BKRW+63.07%
28.39 BKRW+21.36%
23.40 BKRW-24.72%
31.08 BKRW+96.60%
15.81 BKRW-26.66%
21.55 BKRW+39.87%
15.41 BKRW+37.43%
11.21 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kolon Life Science Stock analysis

What does Kolon Life Science do? KOLON Life Science, Inc. generates revenue through its Chemical Business segment, which produces and sells raw drug products, antibacterial agents, water treatment agents, and functional material products for cosmetics. The Bio Business segment focuses on manufacturing and selling bio new medicines based on cell gene therapy products. The company's products target pharmaceutical and environmental markets, with raw drug products serving as essential components for new and generic drugs, while antibacterial agents and water treatment agents address healthcare and environmental purification needs. Functional materials for cosmetics represent a key product line within the Chemical Business segment. The company's revenue streams are derived from the sale of pharmaceutical raw materials, antibacterial agents, water treatment solutions, and cosmetic functional materials under the Chemical Business segment. The Bio Business segment contributes through the commercialization of advanced cell gene therapy-based medicines. Both segments operate within the pharmaceutical and environmental sectors, with the Chemical Business serving as the primary revenue driver for raw materials and environmental products, while the Bio Business targets innovative therapeutic solutions in the biopharmaceutical space. KOLON Life Science, Inc. sells its products to the pharmaceutical industry for drug development and manufacturing, as well as to environmental and cosmetic companies requiring specialized materials. The Chemical Business segment's raw drug products are used by pharmaceutical firms to produce new and generic drugs, while antibacterial agents and water treatment agents are supplied to healthcare and environmental purification sectors. Cosmetic functional materials are sold to the cosmetics industry for product development. The Bio Business segment's cell gene therapy products are targeted at biopharmaceutical companies seeking advanced treatment options. Kolon Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kolon Life Science stock

Current Liabilities of Kolon Life Science is 12.93 B KRW in 2025.

Current Liabilities of Kolon Life Science changed from 133.43 B KRW to 12.93 B KRW, representing a -90.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Kolon Life Science since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Kolon Life Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Kolon Life Science

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Kolon Life Science